Identification of Subclinical Myocardial Dysfunction in Breast Cancer Patients with Metabolic Syndrome after Cancer-Related Comprehensive Therapy

• Published in: Cardiology research and practice Vol. 2021; pp. 6640673 - 7
• Main Authors: Zhang, Feng, Wang, Siyuan, Liang, Siying, Yu, Chao, Li, Sufang, Chen, Hong, Wang, Shu, Zhu, Tiangang
• Format: Journal Article
• Language: English
• Published: United States Hindawi 2021; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Age; Blood pressure; Breast cancer; Cancer; Cancer patients; Cancer therapies; Cardiac patients; Cardiovascular disease; Cardiovascular diseases; Care and treatment; Chemotherapy; Cholesterol; Glucose; Health aspects; Heart; Metabolic syndrome; Monoclonal antibodies; Multivariate analysis; Oncology, Experimental; Patients; Prevention; Radiation therapy; Regression analysis; Risk factors; Targeted cancer therapy; China
• ISSN: 2090-8016; 2090-0597; 2090-0597
• DOI: 10.1155/2021/6640673

Background. Breast cancer patients with metabolic syndrome have an increased risk of cardiovascular disease. These patients are more prone to suffer from cardiotoxicity after anticancer therapy. Patients after completion of cancer-related comprehensive therapy, who show normal myocardial function, may already have subclinical myocardial dysfunction. We sought to evaluate the subclinical myocardial dysfunction in breast cancer patients with metabolic syndrome after cancer-related comprehensive therapy. Methods. In this study, 45 breast cancer patients with metabolic syndrome after completion of cancer-related comprehensive therapy, 45 non-breast cancer patients with metabolic syndrome, and 30 breast cancer patients without metabolic syndrome after therapy were enrolled. Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) were measured using echocardiogram. Results. All the patients had normal LVEF. However, nine breast cancer patients with metabolic syndrome (20%) had GLS that was lower than –17%, while all the noncancer patients had normal GLS. Breast cancer patients with metabolic syndrome had a decrease of GLS and LVEF, compared with noncancer patients with metabolic syndrome. Furthermore, we found that decrease of age was associated with reduction of LVEF and that use of trastuzumab for 1 year was a significant factor associated with reduction of GLS. In addition, breast cancer patients with metabolic syndrome had a decrease of GLS, compared with breast cancer patients without metabolic syndrome after cancer-related therapy. Conclusions. Breast cancer patients with metabolic syndrome after completion of cancer-related comprehensive therapy suffered from subclinical myocardial dysfunction. GLS should be routinely performed to early identify subclinical myocardial damage of patients, in order to prevent the cardiotoxicity of cancer-related comprehensive therapy.